ProKidney Corp. (BMV:PROK)
Mexico · Delayed Price · Currency is MXN 49.03
+1.13 (2.36%)
At close: Sep 18, 2025
ProKidney Company Description
ProKidney Corp., a clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States.
Its lead product candidate, rilparencel, includes autologous selected renal cells (SRC) in Phase 3 and Phase 2 clinical studies in subjects with moderate to severe chronic kidney disease and diabetes.
The company also develops a cryopreserved version of rilparencel that allows for long-term product preservation to be used in Phase 2 and 3 trials of rilparencel.
ProKidney Corp. was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
ProKidney Corp.
| Country | United States |
| Founded | 2015 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 204 |
| CEO | Bruce Culleton |
Contact Details
Address: 2000 Frontis Plaza Blvd. Winston-Salem, Delaware 27103 United States | |
| Phone | 336 999 7028 |
| Website | prokidney.com |
Stock Details
| Ticker Symbol | PROK |
| Exchange | Mexican Stock Exchange |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Bruce Culleton | Chief Executive Officer |
| James Coulston | Chief Financial Officer |
| Anu Biswas | Chief Operating Officer |